We are live on ! Find out more

1,606 hedge funds and large institutions have $133B invested in Pfizer in 2013 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 616 increasing their positions, 724 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more call options, than puts

Call options by funds: $1.22B | Put options by funds: $1.16B

0.06% more ownership

Funds ownership: 73.6%73.66% (+0.06%)

4% less capital invested

Capital invested by funds: $139B → $133B (-$5.46B)

6% less first-time investments, than exits

New positions opened: 72 | Existing positions closed: 77

1% less funds holding

Funds holding: 1,6271,606 (-21)

12% less funds holding in top 10

Funds holding in top 10: 290254 (-36)

15% less repeat investments, than reductions

Existing positions increased: 616 | Existing positions reduced: 724

Holders
1,606
Holders Change
-21
Holders Change %
-1.29%
% of All Funds
52.06%
Holding in Top 10
254
Holding in Top 10 Change
-36
Holding in Top 10 Change %
-12.41%
% of All Funds
8.23%
New
72
Increased
616
Reduced
724
Closed
77
Calls
$1.22B
Puts
$1.16B
Net Calls
+$60.2M
Net Calls Change
+$43.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Victory Capital Management
151
Victory Capital Management
Texas
$126M +$126M +4,635,611 New
Two Sigma Investments
152
Two Sigma Investments
New York
$124M +$124M +4,562,538 New
CBOA
153
Commonwealth Bank of Australia
Australia
$123M -$11.9M -438,214 -9%
D.E. Shaw & Co
154
D.E. Shaw & Co
New York
$123M -$320M -11,763,255 -72%
Janus Henderson Group
155
Janus Henderson Group
United Kingdom
$119M +$433K +15,908 +0.4%
MLICM
156
Metropolitan Life Insurance Company (MetLife)
New York
$119M -$1.53M -56,405 -1%
BCIM
157
British Columbia Investment Management
British Columbia, Canada
$117M -$11.2M -411,992 -9%
EAM
158
Eagle Asset Management
Florida
$116M +$59.8M +2,198,071 +107%
CRM
159
Cramer Rosenthal McGlynn
Connecticut
$116M -$2.61M -95,840 -2%
O
160
OrbiMed
New York
$115M -$25.6M -941,116 -18%
SC
161
Stralem & Co
New York
$114M -$5.15M -189,328 -4%
Caisse de Depot et Placement du Quebec (CDPQ)
162
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$114M -$26.7M -981,695 -19%
NRECA
163
National Rural Electric Cooperative Association
Virginia
$113M
N
164
Nuveen
North Carolina
$112M -$16.9M -621,757 -13%
KCM
165
Kames Capital Management
United Kingdom
$111M -$3.8M -139,614 -3%
Korea Investment Corp
166
Korea Investment Corp
South Korea
$110M -$975K -35,836 -0.9%
AT
167
Alliance Trust
United Kingdom
$106M -$7.71M -283,210 -7%
JFL
168
Jarislowsky, Fraser Ltd
Quebec, Canada
$103M -$2.85M -104,917 -3%
SOMRS
169
State of Michigan Retirement System
Michigan
$103M +$259K +9,529 +0.3%
ACI
170
AMP Capital Investors
Australia
$102M +$5.27M +193,837 +6%
AI
171
Analytic Investors
California
$101M +$46.1M +1,695,599 +84%
Susquehanna International Group
172
Susquehanna International Group
Pennsylvania
$101M -$887M -32,615,407 -90%
SCM
173
Sterling Capital Management
North Carolina
$99.9M -$3.05M -112,262 -3%
PHS
174
PFM Health Sciences
California
$99.2M -$205M -7,541,157 -67%
RRAM
175
River Road Asset Management
Kentucky
$96M -$2.96M -108,825 -3%

PFE Hedge Fund Activity: Q3 2013 in Review

1,606 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2013, worth a combined $133B — down 3.9% from $139B a quarter earlier.

Sellers outnumbered buyers: 77 funds closed out of PFE and 72 opened new positions — a net loss of 5 holders — while 724 trimmed existing stakes and 616 added.

The largest buyer was Capital World Investors, adding an estimated $294M. The largest seller was Susquehanna International Group, cutting an estimated $887M.

  • 1,606 institutional investors held Pfizer (PFE) as of Q3 2013, down from 1,627 in Q2 2013.
  • Funds reported $133B of Pfizer stock for Q3 2013, down 3.9% quarter-over-quarter.
  • 72 funds opened new Pfizer positions in Q3 2013 and 77 closed out, a net change of -5 holders.
  • The largest Pfizer buyer in Q3 2013 was Capital World Investors, an estimated $294M added.
  • The largest Pfizer seller in Q3 2013 was Susquehanna International Group, an estimated $887M sold.

Based on aggregated 13F filings for Q3 2013.